Genocea Biosciences Inc. sell StockNews.com
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 23.03.25. The prediction end date can be changed by StockNews_com at any time.Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Genocea Biosciences Inc. | - | - |
| iShares Core DAX® | 2.594% | -1.158% |
| iShares Nasdaq 100 | 3.553% | -1.727% |
| iShares Nikkei 225® | 0.687% | -8.354% |
| iShares S&P 500 | 2.209% | -0.942% |
Comments by StockNews_com for this prediction
In the thread Genocea Biosciences Inc. diskutieren